Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. Co. uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. We show 13 historical shares outstanding datapoints in our coverage of ACRV's shares outstanding history.
Understanding the changing numbers of ACRV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRV by allowing them to research ACRV shares outstanding history
as well as any other stock in our coverage universe. |
Free ACRV Email Alerts:
Video: Shares Outstanding Importance
